Corporate Accounting Manager at Generation Bio

Cambridge, Massachusetts, United States

Generation Bio Logo
Not SpecifiedCompensation
Senior (5 to 8 years)Experience Level
Full TimeJob Type
UnknownVisa
BiotechnologyIndustries

Requirements

  • Self-motivated with a strategic mindset
  • Ability to manage multiple deliverables and projects in a dynamic environment
  • Attention to detail and quality
  • Knowledge of generally accepted accounting principles (GAAP)
  • Experience with SEC financial reporting (Form 10-Q, 10-K, 8-K)
  • Familiarity with internal controls, Sarbanes-Oxley (SOX), and Oracle quarterly updates testing
  • Ability to work closely with cross-functional teams (Accounts Payable, HR, Legal, Facilities, R&D, IT, service providers, external auditors)
  • Coaching, mentoring, and professional development skills for team members

Responsibilities

  • Assist with the monthly and quarterly close process and drive timely financial reporting in accordance with GAAP
  • Prepare reconciliations and journal entries for areas including Accruals, Prepaids, Equity, Leases, and others as required
  • Review and approve journal entries and account reconciliations
  • Provide coaching, mentoring, and professional development to other team members
  • Assist with the preparation of SEC financial reporting on Form 10-Q, 10-K, and 8-K, including creation of auditable support
  • Perform internal controls for various business processes in compliance with the Company’s internal control framework and SOX
  • Perform Oracle quarterly updates testing
  • Assist in pulling support for external auditors for quarterly reviews, year-end financial statement audit, and SOX 404 audit
  • Assist in the creation and improvement of accounting business processes to improve productivity and operating efficiencies
  • Manage the Company’s stock plan administration consultant, ensuring transactions are entered into E*trade and Computershare
  • Act as a liaison between the stock plan administrator and payroll to ensure transactions are captured in employee payroll records
  • Oversee the Procure to Pay cycle to enable timely and accurate vendor payments
  • Assist in the development of departmental initiatives, goals, and strategies to achieve them

Skills

Account Reconciliations
Journal Entries
Month-End Close
Financial Reporting
GAAP
General Ledger
Audit Coordination

Generation Bio

Develops durable genetic treatments for diseases

About Generation Bio

Generation Bio focuses on developing genetic treatments for both rare and common diseases. Their main product is based on a non-viral genetic medicine platform that includes iqDNA, which is designed to be immune-quiet, and ctLNP, a delivery system that targets specific cells. This platform allows for the delivery of large amounts of genetic material to particular tissues, aiming for long-lasting effects from a single treatment. They use a unique manufacturing process called rapid enzymatic synthesis (RES) that enables them to produce these treatments at scale, potentially reaching hundreds of millions of doses. Unlike many competitors, Generation Bio's approach allows for redosing and adjusting treatment levels based on patient needs. The company's goal is to make genetic medicine more accessible and to address significant medical needs in the population.

Cambridge, MassachusettsHeadquarters
2016Year Founded
$252.9MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
51-200Employees

Risks

40% workforce reduction may impact innovation and project execution.
Lease termination could indicate potential legal or financial disputes.
Financial constraints might limit future R&D investments despite extended cash runway.

Differentiation

Generation Bio's iqDNA evades immune detection, unlike traditional viral vectors.
Their ctLNP system offers targeted delivery to specific tissues and cell types.
RES manufacturing process is scalable, supporting large-scale production of genetic medicines.

Upsides

Strategic reorganization extends cash runway into 2H 2027, supporting long-term R&D.
Partnership with Moderna highlights demand for non-viral delivery systems.
Focus on both rare and prevalent diseases expands market potential significantly.

Land your dream remote job 3x faster with AI